CEO Clips - Cannara Biotech Expands Cannabis Production with Mega Facilities
Cannara Biotech is building its strategy around those factors through two large cultivation facilities designed specifically for cannabis production.

Vertically integrated producer scales capacity to meet growing demand
How is Cannara Biotech scaling cannabis production in Canada?
Cannara Biotech operates two purpose-built cannabis cultivation facilities totaling more than 1.6 million square feet, allowing the company to grow up to 100 tonnes annually as market demand increases.
Cannabis production at scale requires infrastructure, consistency, and operational control, principles that Cannara Biotech has embedded into its strategy through two purpose-built cultivation facilities: a 1 million-square-foot site in Valleyfield and a 605,000-square-foot facility in Farnham, together forming one of the largest cultivation footprints among Canadian licensed producers.
Current output is approximately 50,000 kilograms of cannabis annually, with the ability to scale to 100,000 kilograms per year as additional cultivation zones are activated.
Cannara is also fully vertically integrated, meaning the company manages the entire process from cultivation through finished product manufacturing and distribution to it’s provincial government partners across Canada. This structure allows tighter control over product consistency, quality, and supply chain efficiency.
The company recently announced it’s uplisting to the TSX as a strategy to improve accessibility for investors and increase visibility in Canadian capital markets.
As Canada’s cannabis market matures, scale, efficiency, and brand consistency remain key competitive advantages for licensed producers.
To learn more about Cannara Biotech (TSX: LOVE, OTCQX: LOVFF), please click the request investor info button.
Latest Articles
Hot Companies
You might also like

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.




.jpg)